Literature DB >> 7817828

Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study.

M J Seibel1, H Woitge, C Scheidt-Nave, G Leidig-Bruckner, A Duncan, P Nicol, R Ziegler, S P Robins.   

Abstract

The urinary pyridinium crosslinks pyridinoline (PYD) and deoxypyridinoline (DPD) have been shown to provide valid indices of bone resorption. At present, both crosslink components are determined by reversed-phase HPLC, a time-consuming method precluding the use of these markers for routine purposes. Therefore, efforts have been made to develop simple immunoassays for the rapid measurement of urinary crosslinks, and their application to large-scale osteoporosis screening has been proposed. To evaluate the applicability and diagnostic validity of pyridinium crosslink measurements for screening purposes, urinary concentrations of total and free PYD and DPD were determined by HPLC and immunoassay technique (ELISA) in a sample of 269 individuals (male to female ratio = 130:139; age 50-81 years) recruited at random within a population survey of vertebral osteoporosis. On a molar basis, ELISA measures of crosslink-related epitopes were highly correlated with both total and free PYD and DPD as determined by HPLC (r > 0.82, p < 0.001). Age-specific means for creatinine-corrected total and free pyridinium crosslinks were significantly higher in females than in males (p < 0.001). In both sexes, neither age nor anthropometric variables (weight, height, and body mass index) showed a linear effect on the urinary crosslink/creatinine ratio. On average, 50% of the total amount of urinary crosslinks were present in free form. For both PYD and DPD, this proportion was significantly higher in women than in men (p < 0.05), but no change was observed with age or anthropometric measures. The excretion of pyridinium crosslinks was higher in osteoporotic (n = 18) than in nonosteoporotic individuals (n = 208) from the same population.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7817828     DOI: 10.1002/jbmr.5650090916

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  7 in total

Review 1.  Biochemical markers of bone metabolism in the assessment of osteoporosis: useful or not?

Authors:  M J Seibel
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

2.  Relationship between C-telopeptide pyridinoline cross-links (ICTP) and putative periodontal pathogens in periodontitis.

Authors:  M D Palys; A D Haffajee; S S Socransky; W V Giannobile
Journal:  J Clin Periodontol       Date:  1998-11       Impact factor: 8.728

3.  Biochemical markers of bone turnover: part I: biochemistry and variability.

Authors:  Markus J Seibel
Journal:  Clin Biochem Rev       Date:  2005-11

4.  Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis.

Authors:  Markus J Seibel
Journal:  Clin Biochem Rev       Date:  2006-08

5.  Urinary excretion of type I collagen cross-linked N-telopeptide and serum bone-specific alkaline phosphatase analysis to determine the correlation of age and back-pain related changes in elderly women.

Authors:  Mikio Kamimura; Shigeharu Uchiyama; Kenji Takahara; Hiroyuki Hashidate; Amu Kawaguchi; Hiroyuki Nakagawa
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

6.  Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment.

Authors:  Una Rauchhaus; Franz Werner Schwaiger; Steffen Panzner
Journal:  Arthritis Res Ther       Date:  2009-12-15       Impact factor: 5.156

7.  The influence of gastrectomy on the change of bone metabolism and bone density.

Authors:  S J Kwon; J S Hahm; Y J Cho; Y Ahn; D I Shin
Journal:  Korean J Intern Med       Date:  2000-01       Impact factor: 2.884

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.